Glaxo-Theravance’s Second Lung Drug Wins U.S. Approval

GlaxoSmithKline Plc and Theravance Inc. won approval for the second lung drug in their partnership aimed at treating the third-leading cause of death in the U.S.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.